Arun Thukkani, MD
Interventional Cardiology · Lewiston, MENPI 1467573659
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,281 of the $8,132 with a category attached, or 64.9%. 22 manufacturers reported payments, led by Abbott at 26.4% of the total. Reporting peaked in 2023 at $2,590 and has fallen 70.6% since, to $761 in 2025. Among interventional cardiology clinicians in ME with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 125 payments — averaging $65.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Edwards Lifesciences$2K
- Medtronic$2K
- Abiomed$566
- Livanova USA, Inc.$528
- W. L. Gore & Associates, Inc.$250
- plus $1K from 16 others
What the payments were for
- Travel & lodging$2,85135%
- Food & beverage$5,28165%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 31 | $2,146 |
| Edwards Lifesciences | 26 | $2,013 |
| Medtronic(2 entities) | 19 | $1,551 |
| Abiomed | 14 | $566 |
| Livanova USA, Inc. | 1 | $528 |
| W. L. Gore & Associates, Inc. | 4 | $250 |
| Penumbra, Inc. | 2 | $181 |
| Shockwave Medical, Inc | 1 | $156 |
| Amgen | 7 | $124 |
| Terumo Medical Corporation | 1 | $111 |
| Teleflex LLC | 2 | $104 |
| Acist Medical Systems, Inc. | 2 | $63 |
| Boehringer Ingelheim | 3 | $63 |
| Biosense Webster, Inc. | 1 | $44 |
| Bayer | 2 | $41 |
| Novartis | 2 | $40 |
| Johnson & Johnson | 2 | $38 |
| Sanofi-aventis U.S. LLC | 1 | $25 |
| Stryker | 1 | $25 |
| Irhythm Technologies, Inc. | 1 | $23 |
| Pfizer | 1 | $21 |
| Heartflow, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MitraClip$1,155
- CoreValve Evolut$592
- TandemLife$528
- COREVALVE EVOLUT R$407
- Edwards SAPIEN XT Transcatheter Heart Valve$370
- Indigo System$160
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$156
- TRICLIP$150
- GORE CARDIOFORM Septal Occluder$141
- SAPIEN 3 Ultra RESILIA$133
- ONYX FRONTIER$128
- PASCAL$115
- GlideWire$111
- Heartrail$111
- METACROSS OTW$111
How this compares
$8,132 in reported general payments places this provider in the 95th percentile of 21 interventional cardiology providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 229 | $234,093 |
| EliquisApixaban | 203 | $150,250 |
| MounjaroTirzepatide | 45 | $62,800 |
| Repatha SureclickEvolocumab | 64 | $62,332 |
| EntrestoSacubitril/Valsartan | 24 | $34,294 |
| FarxigaDapagliflozin Propanediol | 19 | $13,810 |
| BrilintaTicagrelor | 18 | $8,978 |
| Atorvastatin Calcium | 225 | $2,634 |
| Rosuvastatin Calcium | 131 | $2,344 |
| Metoprolol Succinate | 171 | $1,841 |
| Ezetimibe | 94 | $1,580 |
| Losartan Potassium | 190 | $1,372 |
| Valsartan | 19 | $1,183 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 60 | $1,126 |
| ClopidogrelClopidogrel Bisulfate | 83 | $900 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $63 | $234,093229 claims |
| PfizerEliquis | $21 | $150,250203 claims |
| NovartisEntresto | $40 | $34,29424 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 21 interventional cardiology providers in Maine.
Other interventional cardiology in Lewiston
- Bryce EinhornLewiston$5K
- Peter HigginsLewiston$4K
- Andrew EisenhauerLewiston$2K
- Michael BerlowitzLewiston$631
- Szymon WiernekScarborough$22K
- Srikanth RadhakrishnanBangor$7K
- Ellie MuellerAugusta$6K
- Jay ShahScarborough$5K
- Matthew McKayBangor$4K
- Thomas EarlBangor$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.